Pure Global
NCT04211844

Metabolic Changes in Chronic HCV Patients Receiving DAAS

Metabolic Changes in Chronic Hepatitis C Virus Patients Receiving Direct Acting Antivirals
Ain Shams University·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
sofosbuvir plus daclatasvir
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Ain Shams University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2019
End date
Apr 01, 2020
Enrollment
100 participants
Primary outcome

Change from baseline Total Lipid Profile within 6 months,Change from baseline Glycosylated Hemoglobin within 6 months,Change from baseline Fasting Blood Glucose within 6 months

Summary

Observational Study to check metabolic changes between two different hepatitis C antiviral
 medication groups. This study will evaluate the impact of different treatments on Serum lipid
 changes, fasting blood glucose and glycated hemoglobin . It will determine if changes are due
 to different Antiviral regimens or due to different Sustained virological response rates.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04211844
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04211844 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently status unknown. The study focuses on Chronic Hepatitis C. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.